# US 2004/0072745 A1 · Therapeutic methods of use for lp229

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072745 A1
- Document ID: US20040072745A1
- Status: Published application
- Kind: A1
- Application number: 10/250,959
- Filed: 2003-07-08
- Published: 2004-04-15
- Earliest claimed: 2003-07-08
- Inventors: Josef Georg Heuer; Kristine Kay Kikly; Eric Wen Su
- Web page: https://patentgrep.com/patent/US20040072745A1

## CPC

- A61K 38/55: Protease inhibitors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of use are provided for the treatment or prevention of poor healing or chronic wounds, skin diseases, sepsis, inflammation, immunodeficiencies, autoimmune diseases, infectious diseases, allergic diseases, and malignancies, particularly those disorders associated with the skin, by administering an LP229 polypeptide, protein, or epitope-recognizing antibody thereof to a patient in need of such therapy.

## Claims

### Claim 1

A method of preventing or treating a disease or pathological condition comprising administering to a patient in need thereof a pharmacologically effective amount of an LP229 polypeptide.

### Claim 2 (depends on 1)

The method of claim 1 wherein the LP229 polypeptide comprises a polypeptide sequence as shown in SEQ ID NO:2 or any biologically active fragment or fusion thereof.

### Claim 3 (depends on 1, 2)

A method as in claim 1 or 2 wherein said disease or pathological condition is a poor healing or chronic wound.

### Claim 4 (depends on 3)

A method as in claim 3 wherein the poor healing or chronic wound is selected from the group consisting of pressure ulcers, diabetic ulcers, venous stasis ulcers, burns, and wounds to tissue in the gastrointestinal tract.

### Claim 5 (depends on 1, 2)

A method as in claim 1 or 2 wherein said disease or pathological condition is selected from the group consisting of skin diseases, sepsis, inflammation, immunodeficiencies, autoimmune diseases, infectious diseases, allergic diseases, and malignancies.

### Claim 6 (depends on 1, 2)

A method as in claim 1 or 2 wherein said disease or condition is exacerbated by massive neutrophil infiltration.

### Claim 7 (depends on 1, 2)

A method as in claim 1 or 2 wherein the patient is a mammal.

### Claim 8 (depends on 1, 2)

A method as in claim 1 or 2 wherein the patient is a human.

### Claim 9 (depends on 1, 2)

A method as in claim 1 or 2 wherein the LP229 polypeptide is administered in a single dose.

### Claim 10 (depends on 1, 2)

A method as in claim 1 or 2 wherein the LP229 polypeptide is administered in multiple doses.

### Claim 11

A method of preventing or treating a disease or pathological condition comprising administering to a patient in need thereof a pharmacologically effective amount of an LP229 epitope-recognizing antibody.

### Claim 12 (depends on 11)

The method of claim 11 wherein said disease or pathological condition is a skin disease, sepsis, inflammation, an immunodeficiency, autoimmune disease, infectious disease, allergic disease, or malignancy.
